药械

订阅

MedSci主页 / 所有栏目 / 药械

J Pharmacol Toxicol Methods：优化的乳酸脱氢酶释放试验用于筛选神经类候选药物

2015-02-16 范伟译 MedSci原创

乳酸脱氢酶药物
关注

背景：乳酸脱氢酶(LDH)释放的定量测定是一种广泛接受的用于测定细胞活性和晚期细胞凋亡的实验。商业性的LDH测定试剂盒主要缺点包括专有配方、有限的优化选择以及高成本，导致了研究应用中重现性的限制。 方法：我们描述了一个新颖的，基于使用者的定制的LDH测定用于筛选胶质保护类候选药物，与其他细胞类型和实验程序相比具有广泛的适用性。 结果：我们开发了一个新颖的、可高度重复性的LDH释放试剂盒，它相比

背景：乳酸脱氢酶(LDH)释放的定量测定是一种广泛接受的用于测定细胞活性和晚期细胞凋亡的实验。商业性的LDH测定试剂盒主要缺点包括专有配方、有限的优化选择以及高成本，导致了研究应用中重现性的限制。

方法：我们描述了一个新颖的，基于使用者的定制的LDH测定用于筛选胶质保护类候选药物，与其他细胞类型和实验程序相比具有广泛的适用性。

结果：我们开发了一个新颖的、可高度重复性的LDH释放试剂盒，它相比于商用的具有类似性能的试剂盒更经济。该试剂盒通过测定在C6星形神经胶质瘤细胞上6-羟基-2,5,7,8-四甲基色烷-2-羧酸抗氧化防护叔丁基化过氧氢-诱导的氧化应激实验进行验证。试剂盒性能是通过直接的比较以及兼容其他方法测定细胞的存活能力，即溴化噻唑蓝四氮唑和 6-羧基-2',7'-二氯荧光素二乙酸酯试验。

与现有的方法比较：新颖的定制的试剂盒和商用的试剂盒CytoTox96®(Promega, Madison, WI)的测定结果在统计学上没有的显著差异。

结论：这个新颖的定制的LDH释放试剂盒具有可重复性的定量测定细胞的存活能力，且成本相比于商用的试剂盒更便宜(约25倍)。除了与商用试剂盒相比，其对所有实验组分和操作的详细描述，在实验条件和设计上提供了更优的控制方案。我们提供一个详细的标准操作程序，这使得我们提供的新颖的试剂盒能较为容易的适应实验的要求。

原始出处

Kaja S1, Payne AJ2, Singh T2, Ghuman JK2, Sieck EK2, Koulen P2.An optimized lactate dehydrogenase release assay for screening of drug candidates in neuroscience. J Pharmacol Toxicol Methods. 2015 Feb 11. pii: S1056-8719(15)00018-0. doi: 10.1016/j.vascn.2015.02.001.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2052397, encodeId=ae91205239e03, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri May 08 14:28:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787165, encodeId=f7f71e8716530, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 29 01:28:00 CST 2015, time=2015-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788163, encodeId=e99c1e8816374, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Feb 01 02:28:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908183, encodeId=d6c119081838c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Sep 27 07:28:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895779, encodeId=8fff1895e7927, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 21 19:28:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995914, encodeId=2092199591423, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Apr 27 14:28:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584337, encodeId=b7a9158433e9b, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Feb 18 07:28:00 CST 2015, time=2015-02-18, status=1, ipAttribution=)]
    2015-05-08 yuanming7

    #候选药物#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2052397, encodeId=ae91205239e03, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri May 08 14:28:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787165, encodeId=f7f71e8716530, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 29 01:28:00 CST 2015, time=2015-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788163, encodeId=e99c1e8816374, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Feb 01 02:28:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908183, encodeId=d6c119081838c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Sep 27 07:28:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895779, encodeId=8fff1895e7927, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 21 19:28:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995914, encodeId=2092199591423, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Apr 27 14:28:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584337, encodeId=b7a9158433e9b, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Feb 18 07:28:00 CST 2015, time=2015-02-18, status=1, ipAttribution=)]
    2015-11-29 jj000001

    #Pharm#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2052397, encodeId=ae91205239e03, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri May 08 14:28:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787165, encodeId=f7f71e8716530, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 29 01:28:00 CST 2015, time=2015-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788163, encodeId=e99c1e8816374, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Feb 01 02:28:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908183, encodeId=d6c119081838c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Sep 27 07:28:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895779, encodeId=8fff1895e7927, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 21 19:28:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995914, encodeId=2092199591423, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Apr 27 14:28:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584337, encodeId=b7a9158433e9b, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Feb 18 07:28:00 CST 2015, time=2015-02-18, status=1, ipAttribution=)]
    2016-02-01 dingxiaobo

    #Pharmacol#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2052397, encodeId=ae91205239e03, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri May 08 14:28:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787165, encodeId=f7f71e8716530, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 29 01:28:00 CST 2015, time=2015-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788163, encodeId=e99c1e8816374, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Feb 01 02:28:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908183, encodeId=d6c119081838c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Sep 27 07:28:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895779, encodeId=8fff1895e7927, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 21 19:28:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995914, encodeId=2092199591423, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Apr 27 14:28:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584337, encodeId=b7a9158433e9b, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Feb 18 07:28:00 CST 2015, time=2015-02-18, status=1, ipAttribution=)]
    2015-09-27 chentianping

    #pharma#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2052397, encodeId=ae91205239e03, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri May 08 14:28:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787165, encodeId=f7f71e8716530, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 29 01:28:00 CST 2015, time=2015-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788163, encodeId=e99c1e8816374, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Feb 01 02:28:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908183, encodeId=d6c119081838c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Sep 27 07:28:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895779, encodeId=8fff1895e7927, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 21 19:28:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995914, encodeId=2092199591423, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Apr 27 14:28:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584337, encodeId=b7a9158433e9b, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Feb 18 07:28:00 CST 2015, time=2015-02-18, status=1, ipAttribution=)]
    2015-03-21 一闲

    #MET#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2052397, encodeId=ae91205239e03, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri May 08 14:28:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787165, encodeId=f7f71e8716530, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 29 01:28:00 CST 2015, time=2015-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788163, encodeId=e99c1e8816374, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Feb 01 02:28:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908183, encodeId=d6c119081838c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Sep 27 07:28:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895779, encodeId=8fff1895e7927, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 21 19:28:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995914, encodeId=2092199591423, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Apr 27 14:28:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584337, encodeId=b7a9158433e9b, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Feb 18 07:28:00 CST 2015, time=2015-02-18, status=1, ipAttribution=)]
    2015-04-27 yb6560

    #MAC#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2052397, encodeId=ae91205239e03, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri May 08 14:28:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787165, encodeId=f7f71e8716530, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 29 01:28:00 CST 2015, time=2015-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788163, encodeId=e99c1e8816374, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Feb 01 02:28:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908183, encodeId=d6c119081838c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Sep 27 07:28:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895779, encodeId=8fff1895e7927, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 21 19:28:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995914, encodeId=2092199591423, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Apr 27 14:28:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584337, encodeId=b7a9158433e9b, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Feb 18 07:28:00 CST 2015, time=2015-02-18, status=1, ipAttribution=)]
    2015-02-18 ms6747015003810650

    #筛选#

    0